Product Description
Cogent Biosciences is developing ACTR-087 as a treatment for multiple myeloma and b-cell lymphoma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03266692, https://clinicaltrials.gov/ct2/show/NCT02776813)
Mechanisms of Action: 4-1BB Inhibitor,CD3 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cogent Biosciences
Company Location: CAMBRIDGE MA 02140
Company CEO: Andrew Robbins
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Lymphoma, B-Cell|Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| UT-201501 | P1 |
Completed |
Lymphoma, B-Cell |
2020-02-12 |
29% |
| ATTCK-17-01 | P1 |
Terminated |
Multiple Myeloma |
2019-10-01 |
29% |
| ATTCK-17-01 | P1 |
Terminated |
Multiple Myeloma |
2019-10-01 |
29% |